



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Stamulumab

Cat. No.:	HY-P99588
CAS No.:	705287-60-1
Target:	TGF- β Receptor
Pathway:	TGF-beta/Smad
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Stamulumab (MYO-029) is a recombinant human IgG1 λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research ^{[1][2]} .		
In Vivo	Stamulumab (MYO-029; ip; 1-10 mg/kg/week for 12 weeks) increases skeletal muscle mass in vivo in a concentration-dependent manner in SCID mice. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia ^[1] . Stamulumab (i.v.; 1, 5, 20, 100 mg/kg/week for 4 weeks) has a central clearance (CL) of 0.25 mL/h/kg in C57/SCID mice ^[1] . Pharmacokinetic Parameters of Stamulumab (MYO-029) ^[1] .		
	C57/SCID mice IV (1-100 mg/kg/week for 4 weeks)	Sprague Dawley rats (2-50 mg/kg; single injection)	Cynomolgus monkeys (10-100 mg/kg/week for 5 or 39 weeks)
CL (mL/h/kg)	0.245	0.542	0.228
Volume of central compartment (mL/kg)	103	58.9	41.8
Distributive clearance (mL/h/kg)		1.79	0.815
MCE has not independently confirmed the accuracy of these methods. They are for reference only.			
Animal Model:	Female SCID mice ^[1]		
Dosage:	1, 2.5, 5, 10 mg/kg		
Administration:	IP; every week for 12 weeks		
Result:	Increased skeletal muscle mass in vivo in a concentration-dependent manner.		

REFERENCES

[1]. P Singh, et al. Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy. Clin Transl Sci. 2016 Dec;9(6):302-310.

[2]. Kathryn R Wagner, et al. A phase I/II trial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008 May;63(5):561-71.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA